Loading...
•
Dec 31, 2021
Viking Therapeutics Q4 2021 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments.
Key Takeaways
Viking Therapeutics reported a net loss of $12.4 million, or $0.16 per share, for the fourth quarter ended December 31, 2021. The company's research and development expenses were $9.8 million, and general and administrative expenses were $2.7 million. The company ended the quarter with $202.1 million in cash, cash equivalents and short-term investments.
Enrollment continued in the Phase 2b VOYAGE trial evaluating VK2809 for the treatment of NASH and fibrosis.
A Phase 1b trial evaluating VK0214 in X-ALD patients was placed on hold pending completion of a preclinical study.
A Phase 1 trial of the novel dual incretin receptor agonist VK2735 is underway.
The company ended the fourth quarter with $202.1 million in cash, cash equivalents and short-term investments.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...